55 research outputs found
Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics
Objectives
To test the ability of a multicriteria decision analysis (MCDA) model to incorporate disparate data sources of varying quality along with clinical judgement in a benefit–risk assessment of six well-known pain-relief drugs.
Methods
Six over-the-counter (OTC) analgesics were evaluated against three favourable effects and eight unfavourable effects by seven experts who specialise in the relief of pain, two in a 2-day facilitated workshop whose input data and judgements were later peer-reviewed by five additional experts.
Key findings
Ibuprofen salts and solubilised emerged with the best benefit–risk profile, followed by naproxen, ibuprofen acid, diclofenac, paracetamol and aspirin.
Conclusions
Multicriteria decision analysis enabled participants to evaluate the OTC analgesics against a range of favourable and unfavourable effects in a group setting that enabled all issues to be openly aired and debated. The model was easily communicated and understood by the peer reviewers, so the model should be comprehensible to physicians, pharmacists and other health professionals
Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics
Objectives : To test the ability of a multi-criteria decision analysis (MCDA) model to incorporate disparate data sources of varying quality along with clinical judgement in a benefit-risk assessment of six well-known pain-relief drugs. Methods: Six OTC analgesics were evaluated against three favourable effects and eight unfavourable effects by seven experts who specialise in the relief of pain, two in a two-day facilitated workshop whose input data and judgements were later peer-reviewed by five additional experts. Key findings: Ibuprofen salts & solubilised emerged with the best benefit-risk profile, followed by naproxen, ibuprofen acid, diclofenac, paracetamol, and aspirin. Conclusions: MCDA enabled participants to evaluate the OTC analgesics against a range of favourable and unfavourable effects in a group setting that enabled all issues to be openly aired and debated. The model was easily communicated and understood by the peer reviewers, so the model should be comprehensible to physicians, pharmacists, and other health professional
Submucosal diclofenac for acute postoperative pain in third molar surgery: A randomized, controlled clinical trial
Diclofenac sodium is a widely used nonsteroidal anti-inflammatory drug (NSAID) for relief of inflammatory pain. A recent formulation combines this drug with hydroxypropyl-β-cyclodextrin (HPβCD) to improve its solubility and to enable subcutaneous administration. Previous studies confirmed the efficacy of this combination. This study’s aim was to evaluate the efficacy, safety, and local tolerability of diclofenac HPβCD administered as a local submucosal injection prior to lower third molar surgery. We conducted a prospective, randomized, double-blind, placebo-controlled, parallel-group phase II single-center study. Seventy-five patients requiring mandibular third molar surgery were randomized into 1 of 5 groups: 5 mg/1 mL diclofenac HPβCD, 12.5 mg/1 mL diclofenac HPβCD, 25 mg/1 mL diclofenac HPβCD, 50 mg/1 mL diclofenac HPβCD, or 1 mL placebo. The respective study drug was injected into the mucosal tissue surrounding the surgical site prior to surgery following achievement of local anesthesia. The primary outcome measure was the area under the curve (AUC) of cumulative pain scores from end of surgery to 6 h postsurgery. This demonstrated a global treatment effect between the active groups and placebo, hence confirming the study drug’s efficacy (P = 0.0126). Secondary outcome measures included the time until onset of pain and the time until patients required rescue medication, both showing statistical significance of the study drug compared to placebo (P < 0.0161 and P < 0.0001, respectively). The time until rescue medication ranged between 7.8 h (for 25 mg/1 mL diclofenac HPβCD) and 16 h (for 50 mg/1 mL diclofenac HPβCD). Interestingly, the 5-mg/1-mL solution appeared superior to the 12.5-mg/1-mL and 25-mg/1-mL solutions (time until rescue medication = 12.44 h). A total of 14% of patients experienced minor adverse drug reactions (ADRs), of which 2 cases demonstrated flap necrosis. These resolved without further intervention. The study results overall indicate efficacy, safety, and relative tolerability of diclofenac HPβCD used locally as a submucosal injection prior to third molar surgery (ClinicalTrials.gov NCT01706588)
Inhibition by cartilage and bone marrow fractions of cartilage resporption induced by interleukin-1 and tumour necrosis factor
Fine structural damage to the intestinal mucosa induced by two non-steroid anti-inflammatory drugs of varying potency as prostaglandin synthesis inhibitors
569 EFFECTS OF RIBONUCLEINATE COMPONENTS OF OSTEOCHONDRINR S OSTEOARTHRITIS THERAPY ON FORMATION AND ACTIVITY OF HUMAN OSTEOCLASTS IN VITRO
569 EFFECTS OF RIBONUCLEINATE COMPONENTS OF OSTEOCHONDRINR S OSTEOARTHRITIS THERAPY ON FORMATION AND ACTIVITY OF HUMAN OSTEOCLASTS IN VITRO
- …